Evidence map›Paper›PMID 25870060›Full record

ArticleAntimicrobial agents and chemotherapy2015

Blocking Hsp70 enhances the efficiency of amphotericin B treatment against resistant Aspergillus terreus strains.

Michael Blatzer, Gerhard Blum, Emina Jukic, Wilfried Posch, Peter Gruber, Markus Nagl, Ulrike Binder, Elisabeth Maurer, Bettina Sarg, Herbert Lindner and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Amphotericin B Resistance inbioRxiv : the preprint server for biology · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Response of Fusarium oxysporum soil isolate to amphotericin B and fluconazole at the proteomic level.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Article
  8. Accelerating the understanding ofCurrent research in microbial sciences · 2024
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Frontiers in fungal biology · 2022
    Review
  14. Review
  15. Efficacy of LAMB against Emerging Azole- and Multidrug-ResistantJournal of fungi (Basel, Switzerland) · 2020
    Article
  16. Review
  17. Microorganisms · 2020
    Review
  18. Article
  19. Journal of fungi (Basel, Switzerland) · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Michael BlatzerDivision of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Gerhard BlumDivision of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Emina JukicDivision of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Wilfried PoschDivision of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Peter GruberDivision of Medical Biochemistry, Medical University of Innsbruck, Innsbruck, Austria.
Markus NaglDivision of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Ulrike BinderDivision of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Elisabeth MaurerDivision of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Bettina SargBiocenter, Division of Clinical Biochemistry, Medical University of Innsbruck, Innsbruck, Austria.
Herbert LindnerBiocenter, Division of Clinical Biochemistry, Medical University of Innsbruck, Innsbruck, Austria.
Cornelia Lass-FlörlDivision of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Doris WilflingsederDivision of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria doris.wilflingseder@i-med.ac.at.
Innsbruck Medical University · ATUniversität Innsbruck · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The polyene antifungal amphotericin B (AmB) is widely used to treat life-threatening fungal infections. Even though AmB resistance is exceptionally rare in fungi, most Aspergillus terreus isolates exhibit an intrinsic resistance against the drug in vivo and in vitro. Heat shock proteins perform a fundamental protective role against a multitude of stress responses, thereby maintaining protein homeostasis in the organism. In this study, we elucidated the role of heat shock protein 70 (Hsp70) family members and compared resistant and susceptible A. terreus clinical isolates. The upregulation of cytoplasmic Hsp70 members at the transcriptional as well as translational levels was significantly higher with AmB treatment than without AmB treatment, particularly in resistant A. terreus isolates, thereby indicating a role of Hsp70 proteins in the AmB response. We found that Hsp70 inhibitors considerably increased the susceptibility of resistant A. terreus isolates to AmB but exerted little impact on susceptible isolates. Also, in in vivo experiments, using the Galleria mellonella infection model, cotreatment of resistant A. terreus strains with AmB and the Hsp70 inhibitor pifithrin-μ resulted in significantly improved survival compared with that achieved with AmB alone. Our results point to an important mechanism of regulation of AmB resistance by Hsp70 family members in A. terreus and suggest novel drug targets for the treatment of infections caused by resistant fungal isolates.

Indexed as

Amphotericin BAnimalsAntifungal AgentsAspergillosisAspergillusDrug Resistance, FungalDrug Therapy, CombinationHSP70 Heat-Shock ProteinsMicrobial Sensitivity TestsMothsSulfonamides2-phenylacetylenesulfonamideAmphotericin BAntifungal AgentsHSP70 Heat-Shock ProteinsSulfonamides

Identifiers

PMID25870060
PMCPMC4468683
OpenAlexW1997350440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.